Skip to Content, Navigation, or Footer.
Logo of The Spectrum
Tuesday, April 20, 2021
The independent student publication of The Unversity at Buffalo, since 1950

COVID-19 vaccine developed by UB startup enters human trials

EuCorVac-19 is a liquid injection that can be stored and distributed at refrigerated temperatures

<p>EuCorVac-19 generated strong immune responses in animal models and was approved for combined phase 1 and 2 clinical trials by the South Korean Ministry of Food and Drug Safety in January.</p>

EuCorVac-19 generated strong immune responses in animal models and was approved for combined phase 1 and 2 clinical trials by the South Korean Ministry of Food and Drug Safety in January.

A COVID-19 vaccine candidate developed by a UB spinoff company has progressed to human trials in South Korea, according to a UBNow story.

The vaccine candidate, called EuCorVac-19, was jointly developed by Buffalo biotech company POP Biotechnologies and South Korean biotech company EuBiologics. POP Biotechnologies was founded in 2015 by former UB students Kevin Carter and Jonathan Smyth and UB faculty member Jonathan Lovell.

EuCorVac-19 is a liquid injection that can be stored and distributed at refrigerated temperatures, unlike the ultra-cold storage the PfizerBioNTech vaccine requires. The candidate generated strong immune responses in animal models and was approved for combined phase 1 and 2 clinical trials by the South Korean Ministry of Food and Drug Safety in January.

The first phase will include 50 healthy Korean adults and tests for safety, tolerance and immune response. The second phase will include 230 adults and tests for immune response and dosage. The companies hope to begin the third phase later this year.

“Commencing first-in-human trials is a monumental step forward for our technology,” Smyth said in the release. “Achieving this critical milestone provides validation toward not only serving this unprecedented global crisis, but also provides invaluable support toward our platform’s development, further enabling the creation of new vaccines with tremendous potential to alleviate suffering worldwide.”

Before the pandemic, POP Bio primarily focused on developing cancer therapies and a vaccine against HIV using something called Spontaneous Nanoliposome Antigen Particleization (SNAP), a vaccine-delivery platform. But last March, the company began working to develop an effective COVID-19 vaccine candidate using SNAP, a decision POP Bio hopes will not only benefit the fight against COVID-19, but the fight against HIV as well.

“Because SNAP is a vaccine-platform technology, it could be applicable to any vaccine-related indication, for both chronic and infectious diseases,” Lovell said. “In-human testing for the COVID-19 vaccine will de-risk the technology for other indications too.”

POP Biotechnologies won the UB School of Management and UB Office of Business and Entrepreneur Partnerships’ Henry A. Panasci Jr. Technology Entrepreneurship Competition in 2015. POP Bio has worked from UB’s Incubator @ Baird, a research park for startup companies, since 2017.

Justin Weiss is the managing editor and can be reached at justin.weiss@ubspectrum.com

Support your local paper
Donate Today
The Spectrum has been covering the University at Buffalo since 1950, your donation today could help #SaveStudentNewsrooms. Please consider giving today.

JUSTIN WEISS
justin-weiss-headshot.jpg

Justin Weiss is the The Spectrum's managing editor. In his free time, he can be found hiking, playing baseball or throwing things at his TV when his sports teams aren't winning. His words have appeared in Elite Sports New York and the Long Island Herald.

Comments


Popular









Powered by SNworks Solutions by The State News
All Content © 2021 The Spectrum